- Joined
- May 30, 2005
- Messages
- 21,274
- Reaction score
- 12,407
Medicare Part D beneficiaries received more than 1.2 billion total days of BZDs at a cost of more than US$374 million, which accounted for 2.3% of all Part D medication days. PCPs prescribed 61.9% of all BZDs overall, or more than 728 million of all BZD days.
Short-acting BZDs were prescribed for 91.1% of BZD days, with alprazolam accounting for 38.2% of all BZD days, followed by lorazepam (24.3%), clonazepam (18.3%), temazepam (9.8%), triazolam (0.2%), oxazepam (0.2%), and estazolam (0.1%).
Long-acting BZDs were prescribed for 8.9% of BZD days: diazepam (8.2%), clorazepate (0.6%), and chlordiazepoxide (0.1%).
From medscape medical news.
Short-acting BZDs were prescribed for 91.1% of BZD days, with alprazolam accounting for 38.2% of all BZD days, followed by lorazepam (24.3%), clonazepam (18.3%), temazepam (9.8%), triazolam (0.2%), oxazepam (0.2%), and estazolam (0.1%).
Long-acting BZDs were prescribed for 8.9% of BZD days: diazepam (8.2%), clorazepate (0.6%), and chlordiazepoxide (0.1%).
From medscape medical news.